GlycoMimetics, Inc. (GLYC) News
Filter GLYC News Items
GLYC News Results
|Loading, please wait...|
GLYC News Highlights
- For GLYC, its 30 day story count is now at 6.
- Over the past 23 days, the trend for GLYC's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- MD are the most mentioned tickers in articles about GLYC.
Latest GLYC News From Around the Web
Below are the latest news stories about Glycomimetics Inc that investors may wish to consider to help them evaluate GLYC as an investment opportunity.
Good morning, and thank you for joining the GlycoMimetics call. Brian will follow Rachel to provide an overview of the company's financial position, and we'll then open the call for Q&A. Our Chief Scientific Officer, Dr. John Magnani; and our Chief Medical Officer, Dr. Eric Feldman will join us in the Q&A to address your questions.
GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the quarter ended March 31, 2021 and highlighted recent company events. Cash and cash equivalents at March 31, 2021 were $132.5 million.
NEW YORK, NY / ACCESSWIRE / May 3, 2021 / GlycoMimetics, Inc. (NASDAQ:GLYC) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 3, 2021 at 8:30 AM Eastern Time.
GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that it will host a conference call and webcast to report first quarter financial results on Monday, May 3, 2021, at 8:30 a.m. ET.
Positive Findings From Phase 1b Trial of GlycoMimetics’ GMI-1359 To Be Presented at AACR 2021 Meeting
GlycoMimetics, Inc. (Nasdaq: GLYC) today announces that a Phase 1b trial of GMI-1359, being conducted at Duke University Cancer Center, showed evidence of on-target effects, immune-activation and cell mobilization in the initial two patients treated with the Company’s dual antagonist of E-selectin and CXCR4. Dorothy Sipkins, MD, PhD, Associate Research Professor in Pharmacology and Cancer Biology at Duke University School of Medicine, will present results from the proof-of-concept clinical study as well as a separate preclinical study supporting the positive biologic findings of the Phase 1b study. The presentation will be made at the American Association of Cancer Research (AACR) 2021 Annual Meeting, which is being held virtually on April 10-15 and May 17-21. GMI-1359 is GlycoMimetics’...
GlycoMimetics to Present at AACR 2021 Meeting on Positive Therapeutic Effects of GMI-1757 in a Pancreatic Adenocarcinoma Model
GlycoMimetics, Inc. (Nasdaq: GLYC) today announces that an abstract presenting the results of a recent preclinical study on the therapeutic effects of GMI-1757, a new glycomimetic with dual antagonism to E-selectin and galectin-3, has been accepted for a poster presentation at the American Association of Cancer Research (AACR) 2021 Annual Meeting, to be held virtually on April 10-15 and May 17-21.
Gainers: [[GLYC]] +3.5%. [[CBAY]] +2.6%. [[KPTI]] +2.6%. [[GMAB]] +2.5%. [[SYRS]] +2.4%.Losers: [[VECT]] -8.1%. [[TCRR]] -2.4%. [[JFIN]] -2.3%. [[CENX]] -2.2%. [[GURE]] -1.8%....
Apollomics, Inc Doses First Patient in Phase 1 Clinical Trial in China of GlycoMimetics’ Uproleselan for the Treatment of AML
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics (Nasdaq: GLYC) today announced that Apollomics has dosed the first patient in China in a Phase 1 clinical trial of APL-106 (uproleselan injection) for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML). In February of this year, Apollomics initiated two Phase 1 study sites in Greater China. “Dosing of the first patient in Greater China is a significant accomplishment for Apollomics. Equally important is the fact that A
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the fourth quarter and year ended December 31, 2020, and highlighted recent Company events, including several accomplishments reported to date in 2021. Cash and cash equivalents at December 31, 2020 were $137.0 million. “During 2020, we remained on track to complete enrollment of our uproleselan pivotal trial in the second half of 2021. Uproleselan continues to have strong support from c
Image source: The Motley Fool. GlycoMimetics Inc (NASDAQ: GLYC)Q4 2020 Earnings CallMar 2, 2021, 8:30 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood morning, and thank you all for joining the GlycoMimetics call.